Bio

David, the co-practice group leader of the firm’s Mergers and Acquisitions group, guides clients from across the country and economic sectors through their most complicated M&A transactions, consistently providing practical business solutions to complex legal and financial issues.  Through precision, experience, and dedication to his clients’ success, David structures transactions in highly technical and regulated industries that maximize value and minimize key risks.  In doing so, clients ranging from technology and life sciences companies to private equity funds, venture capital funds, family offices, and their portfolio companies praise his combination of efficient and cost-effective services of the highest caliber with his plain-English, common sense guidance.   

Prior to joining the firm in 2008, David practiced with a multinational law firm.

David received his B.A., summa cum laude, from Duke University and his J.D., cum laude, from New York University School of Law. Before transferring to NYU, he attended Harvard Law School where he was an editor of the Journal of Law and Public Policy. 

  • Listed among The Best Lawyers in America: Corporate Law (2021-2024), Corporate Governance Law (2022-2024)
  • Listed among Business North Carolina Magazine Legal Elite: Business (2022)
  • Listed among North Carolina Super Lawyers “Rising Stars” Securities and Corporate Finance (2010, 2012, 2013)
  • North Carolina State Bar
  • North Carolina Bar Association
  • New York State Bar
  • Board of Directors, American Red Cross—Triangle Area Chapter; Philanthropy Committee Chairman (2017-2021)
  • Member, North Carolina Children’s Hospital Board of Visitors (2010-2016)
  • Represented developer of biological crop protection products in sale of biofungicide to biopesticide development company
  • Represented public clinical-stage biotechnology company in acquisition of privately held biotechnology development company
  • Represented insurance holding company in acquisition of insurance company
  • Represented digital marketing agency in sale to platform marketing services business
  • Represented a leading U.S. clinical management platform focusing on drug and health testing services in sale to global provider of background screening and identity services
  • Represented flyExclusive, a leading provider of premium jet charter experiences, in its de-SPAC transaction valued at $600 million and subsequent listing as a publicly traded company on the NYSE American stock exchange
  • Represented provider of partner relationship management and through-channel marketing automation software in a $70+ million sale of control of the company to private equity sponsor
  • Represented public biopharmaceuticals company in sale of rights to royalties and development milestone payments
  • Represented targeted radiodiagnostics and radiotherapeutics developer in its sale to biopharmaceutical company.
  • Represented diversified environmental services company in $1.2 billion acquisition of solid waste company